Exin Therapeutics

Exin Therapeutics is pioneering a novel approach to drug discovery for neurotherapeutics, leveraging artificial intelligence and high-throughput mouse studies to identify compounds that modulate neural activity within the brain. The company's initial focus is on developing treatments for epilepsies associated with autism and Parkinson's disease, with the long-term potential to address a wide spectrum of neurological disorders characterized by neural activity dysfunction. Their research and development efforts are driven by sophisticated AI models trained on extensive, multimodal mouse data generated internally. The founding team comprises three neuroscientists with training from Oxford University, supported by a Scientific Advisory Board with experience from Harvard, Science Corp (formerly Neuralink), EPFL, Meta, and UCL. Within a short timeframe of 1.5 months since establishing operations in South San Francisco, Exin Therapeutics has successfully established and operated an animal laboratory, achieved proof-of-concept in mice, developed a multimodal AI model to guide screening, and filed two provisional patents, all while utilizing less than half of their Y Combinator funding.